Cancer Res Treat.  2022 Jul;54(3):644-650. 10.4143/crt.2022.187.

Palliative Sedation in End-of-Life Patients in Eastern Asia: A Narrative Review

• Lee SH
• Kwon JH
• Won YW
• Kang JH

• KMID: 2531311
• DOI: http://doi.org/10.4143/crt.2022.187

Abstract

Although palliative sedation (PS) is a common practice in the palliative care of cancer patients in Western countries, there is little related research on the practice in Korea. PS can be classified into several categories according to sedation level and continuity. PS is clearly distinct from euthanasia. While euthanasia is illegal and regarded as unethical in Korea, there is little ethical and legal controversy about PS in terms of the doctrine of double effect. Most studies have asserted that PS does not shorten the survival of terminal cancer patients. Since preference for PS heavily depends on stakeholder value, it should be preceded by shared decision-making through full communication among the patient, family members, and medical team. This is a narrative review article analyzing previous studies, especially from the three Eastern Asian countries, Korea, Japan and Taiwan, which share similar cultures compared with Western countries. Practical issues concerning PS—for example, prevalence, type and dosage of medications, salvage medication, timing of its initiation, and assessment—are described in detail.

Keyword

End of life; Palliative care; Sedation; Refractory symptoms

Reference

References

1. Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage. 2007; 34:94–104.

2. Maltoni M, Setola E. Palliative sedation in patients with cancer. Cancer Control. 2015; 22:433–41.

3. Gurschick L, Mayer DK, Hanson LC. Palliative sedation: an analysis of International Guidelines and Position Statements. Am J Hosp Palliat Care. 2015; 32:660–71.

4. Korean Society of Critical Care Medicine. Korean professional consensus for comfort care and withdrawing/withholding in the intensive care unit. Seoul: Korean Society of Critical Care Medicine;2019.

5. National Cancer Center, Ministry of Health and Welfare. Cancer pain management guideline. 6th ed. Goyang: National Cancer Center;2019.

6. Shin J, Chang YJ, Park SJ, Choi JY, Kim SH, Choi YS, et al. Clinical practice guideline for care in the last days of life. Korean J Hosp Palliat Care. 2020; 23:103–13.

7. Jackson WC. Palliative sedation vs. terminal sedation: what’s in a name? Am J Hosp Palliat Care. 2002; 19:81–2.

8. Twycross R. Reflections on palliative sedation. Palliat Care. 2019; 12:1178224218823511.

9. Lipuma SH. Continuous sedation until death as physician-assisted suicide/euthanasia: a conceptual analysis. J Med Philos. 2013; 38:190–204.

10. Sheldon T. “Terminal sedation” different from euthanasia, Dutch ministers agree. BMJ. 2003; 327:465.

11. Kendall CE. At the coalface: medical ethics in practice: a double dose of double effect. J Med Ethics. 2000; 26:204–5.

12. Maeda I, Morita T, Yamaguchi T, Inoue S, Ikenaga M, Matsumoto Y, et al. Effect of continuous deep sedation on survival in patients with advanced cancer (J-Proval): a propensity score-weighted analysis of a prospective cohort study. Lancet Oncol. 2016; 17:115–22.

13. Yokomichi N, Yamaguchi T, Maeda I, Mori M, Imai K, Shirado Naito A, et al. Effect of continuous deep sedation on survival in the last days of life of cancer patients: a multicenter prospective cohort study. Palliat Med. 2022; 36:189–99.

14. Schur S, Weixler D, Gabl C, Kreye G, Likar R, Masel EK, et al. Sedation at the end of life: a nation-wide study in palliative care units in Austria. BMC Palliat Care. 2016; 15:50.

15. Morita T, Hirai K, Akechi T, Uchitomi Y. Similarity and difference among standard medical care, palliative sedation therapy, and euthanasia: a multidimensional scaling analysis on physicians’ and the general population’s opinions. J Pain Symptom Manage. 2003; 25:357–62.

16. Han JH, Chun HS, Kim TH, Kim RB, Kim JH, Kang JH. Preference and performance fidelity of modified Korean Physician Order for Life-Sustaining Treatment (MK-POLST) items in hospice patients with cancer. Korean J Hosp Palliat Care. 2019; 22:198–206.

17. Morita T, Ikenaga M, Adachi I, Narabayashi I, Kizawa Y, Honke Y, et al. Concerns of family members of patients receiving palliative sedation therapy. Support Care Cancer. 2004; 12:885–9.

18. Shen HS, Chen SY, Cheung DS, Wang SY, Lee JJ, Lin CC. Differential family experience of palliative sedation therapy in specialized palliative or critical care units. J Pain Symptom Manage. 2018; 55:1531–9.

19. Morita T, Ikenaga M, Adachi I, Narabayashi I, Kizawa Y, Honke Y, et al. Family experience with palliative sedation therapy for terminally ill cancer patients. J Pain Symptom Manage. 2004; 28:557–65.

20. Eun Y, Hong IW, Bruera E, Kang JH. Qualitative study on the perceptions of terminally ill cancer patients and their family members regarding end-of-life experiences focusing on palliative sedation. J Pain Symptom Manage. 2017; 53:1010–6.

21. Belar A, Arantzamendi M, Menten J, Payne S, Hasselaar J, Centeno C. The decision-making process for palliative sedation for patients with advanced cancer-analysis from a systematic review of prospective studies. Cancers (Basel). 2022; 14:301.

22. Morita T, Oyama Y, Cheng SY, Suh SY, Koh SJ, Kim HS, et al. Palliative care physicians’ attitudes toward patient autonomy and a good death in East Asian countries. J Pain Symptom Manage. 2015; 50:190–9.

23. Yamaguchi T, Maeda I, Hatano Y, Suh SY, Cheng SY, Kim SH, et al. Communication and behavior of palliative care physicians of patients with cancer near end of life in three East Asian countries. J Pain Symptom Manage. 2021; 61:315–22.

24. Caraceni A, Speranza R, Spoldi E, Ambroset CS, Canestrari S, Marinari M, et al. Palliative sedation in terminal cancer patients admitted to hospice or home care programs: does the setting matter? Results from a national multicenter observational study. J Pain Symptom Manage. 2018; 56:33–43.

25. Kim YS, Song HN, Ahn JS, Koh SJ, Ji JH, Hwang IG, et al. Sedation for terminally ill cancer patients: a multicenter retrospective cohort study in South Korea. Medicine (Baltimore). 2019; 98:e14278.

26. Won YW, Chun HS, Seo M, Kim RB, Kim JH, Kang JH. Clinical patterns of continuous and intermittent palliative sedation in patients with terminal cancer: a descriptive, observational study. J Pain Symptom Manage. 2019; 58:65–71.

27. van Deijck RH, Hasselaar JG, Krijnsen PJ, Gloudemans AJ, Verhagen SC, Vissers KC, et al. The practice of continuous palliative sedation in long-term care for frail patients with existential suffering. J Palliat Care. 2015; 31:141–9.

28. Rodrigues P, Crokaert J, Gastmans C. Palliative sedation for existential suffering: a systematic review of argument-based ethics literature. J Pain Symptom Manage. 2018; 55:1577–90.

29. Elwyn G, Durand MA, Song J, Aarts J, Barr PJ, Berger Z, et al. A three-talk model for shared decision making: multistage consultation process. BMJ. 2017; 359:j4891.

30. Bodnar J. A review of agents for palliative sedation/continuous deep sedation: pharmacology and practical applications. J Pain Palliat Care Pharmacother. 2017; 31:16–37.

31. Morita T, Chinone Y, Ikenaga M, Miyoshi M, Nakaho T, Nishitateno K, et al. Efficacy and safety of palliative sedation therapy: a multicenter, prospective, observational study conducted on specialized palliative care units in Japan. J Pain Symptom Manage. 2005; 30:320–8.

32. Hui D, Dev R, Bruera E. Neuroleptics in the management of delirium in patients with advanced cancer. Curr Opin Support Palliat Care. 2016; 10:316–23.

33. Hui D, Frisbee-Hume S, Wilson A, Dibaj SS, Nguyen T, De La Cruz M, et al. Effect of lorazepam with haloperidol vs haloperidol alone on agitated delirium in patients with advanced cancer receiving palliative care: a randomized clinical trial. JAMA. 2017; 318:1047–56.

34. Fredheim OM, Skulberg IM, Magelssen M, Steine S. Clinical and ethical aspects of palliative sedation with propofol: a retrospective quantitative and qualitative study. Acta Anaesthesiol Scand. 2020; 64:1319–26.

35. Setla J, Pasniciuc SV. Home palliative sedation using phenobarbital suppositories: time to death, patient characteristics, and administration protocol. Am J Hosp Palliat Care. 2019; 36:871–6.

36. Belar A, Arantzamendi M, Payne S, Preston N, Rijpstra M, Hasselaar J, et al. How to measure the effects and potential adverse events of palliative sedation? An integrative review. Palliat Med. 2021; 35:295–314.

37. Bruinsma S, Rietjens J, van der Heide A. Palliative sedation: a focus group study on the experiences of relatives. J Palliat Med. 2013; 16:349–55.

38. Swart SJ, Brinkkemper T, Rietjens JA, Blanker MH, van Zuylen L, Ribbe M, et al. Physicians’ and nurses’ experiences with continuous palliative sedation in the Netherlands. Arch Intern Med. 2010; 170:1271–4.

39. Schildmann EK, Schildmann J, Kiesewetter I. Medication and monitoring in palliative sedation therapy: a systematic review and quality assessment of published guidelines. J Pain Symptom Manage. 2015; 49:734–46.